 BOSTON, May 03, 2022 GLOBE NEWSWIRE -- X4 Pharmaceuticals, Inc. Nasdaq: XFOR, a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that it will report its financial results for the first quarter ended March 31, 2022, and provide an update on recent business highlights, on May 12, 2022. 